Pharmacological treatment of sepsis

Fundamental & Clinical Pharmacology
Armand R J GirbesRob J M Strack van Schijndel

Abstract

The incidence of sepsis, the combination of a systemic inflammatory response syndrome and documented infection, is as high as up to 95 cases per 100,000 people per year. The understanding of the pathophysiology of sepsis has much increased over the last 20 years. However, sepsis combined with shock is still associated with a high mortality rate varying from 35 to 55%. Causative treatment, source control and antibiotics started as soon as possible, are the cornerstone of therapy in combination with symptomatic treatment in the ICU. The pharmacological interventions, including fluid resuscitation, vasoactive drugs and adjunctive drugs such as steroids, activated protein C are discussed. The possible beneficial role of strict glucose control is also addressed. Since many drug intervention studies were negative, lessons should be learned from earlier experiences for future trials. Source control and level of intensive care should be eliminated as confounders.

References

Jan 1, 1997·Clinical and Experimental Hypertension : CHE·A R Girbes, A J Smit
Mar 10, 2001·The New England Journal of Medicine·G R BernardUNKNOWN Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
Jan 17, 2002·The New England Journal of Medicine·G van den BergheR Bouillon
Jan 17, 2002·The New England Journal of Medicine·E RiversUNKNOWN Early Goal-Directed Therapy Collaborative Group
Aug 21, 2002·JAMA : the Journal of the American Medical Association·Djillali AnnaneEric Bellissant
Nov 7, 2002·JAMA : the Journal of the American Medical Association·Peter J PronovostTammy L Young
Jul 10, 2003·JAMA : the Journal of the American Medical Association·Edward AbrahamUNKNOWN OPTIMIST Trial Study Group
Dec 31, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rodger D MacArthurWilliam Barchuk
May 26, 2004·Lancet·Kees H Polderman, Armand R J Girbes
May 28, 2004·The New England Journal of Medicine·Simon FinferUNKNOWN SAFE Study Investigators
Aug 4, 2004·BMJ : British Medical Journal·Djillali AnnaneYizhak Kupfer
Aug 4, 2004·Circulation·Yaniv AlmogAbraham Danon
Jan 14, 2005·The International Journal of Artificial Organs·A R J Girbes
Sep 30, 2005·The New England Journal of Medicine·Edward AbrahamUNKNOWN Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group
Dec 24, 2005·Critical Care Medicine·Kees H Polderman, Armand R J Girbes
Feb 3, 2006·The New England Journal of Medicine·Greet Van den BergheRoger Bouillon
May 23, 2006·The New England Journal of Medicine·UNKNOWN National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials NetworkAndrea L Harabin
Oct 5, 2006·Intensive Care Medicine·François LauzierOlivier Lesur
Dec 29, 2006·Pharmacotherapy·Christopher P MartinJay I Peters
Feb 27, 2007·Intensive Care Medicine·Christoph EngelKonrad Reinhart
Mar 14, 2007·Lancet·Simon NadelUNKNOWN REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group
Dec 7, 2007·Intensive Care Medicine·R Phillip DellingerJean-Louis Vincent
Dec 26, 2007·Critical Care Medicine·R Phillip DellingerUNKNOWN World Federation of Societies of Intensive and Critical Care Medicine
Jan 11, 2008·The New England Journal of Medicine·Charles L SprungUNKNOWN CORTICUS Study Group
Jan 11, 2008·The New England Journal of Medicine·Frank M BrunkhorstUNKNOWN German Competence Network Sepsis (SepNet)
Feb 29, 2008·The New England Journal of Medicine·James A RussellUNKNOWN VASST Investigators

❮ Previous
Next ❯

Citations

Jan 10, 2017·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Omar A HarasstaniDaud A Israf
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Arturo J Martí-CarvajalAndrés Felipe Cardona
Oct 10, 2012·Clinical Chemistry and Laboratory Medicine : CCLM·Jeroen H GerritsBert Loef
Sep 9, 2009·Expert Review of Anti-infective Therapy·Giuseppe A Marraro
May 14, 2020·Journal of Personalized Medicine·Sean D McCarthyBrendan D Higgins
Apr 13, 2017·Indian Journal of Critical Care Medicine : Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine·Shahed OmarJoel M Dulhunty

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Langenbeck's Archives of Surgery
Tetsuji Fujita, Katsuhiko Yanaga
Critical Care Medicine
Benjamin D LorenzSumati Nambiar
Critical Care : the Official Journal of the Critical Care Forum
Heitor A Paula Neto, Paul Kubes
AACN Advanced Critical Care
Margaret S Ruggiero
© 2022 Meta ULC. All rights reserved